Trial Profile
A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Olaptesed pegol (Primary) ; Filgrastim
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Sponsors NOXXON Pharma AG
- 26 Sep 2014 New trial record